Author

S. Lawson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. Ritz· 1 shared A. VanGaest· 1 shared C. W. Ryan· 1 shared C. Xue· 1 shared D. Garg· 1 shared D. S. Derrick· 1 shared G. V. Thomas· 1 shared H.-w. Lue· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Ritz

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Identification of clinical combination therapies to induce durable responses in kidney cancers

H.-w. Lue, D. S. Derrick, S. Rao, A. VanGaest, L. Cheng, J. Podolak, S. Lawson, C. Xue, D. Garg, R. White, C. W. Ryan, J. M. Drake, A. Ritz, L. M. Heiser, G. V. Thomas

This study identifies a synergistic combination of cabozantinib and dasatinib that reduces viability and induces tumor regression in NCCRCC, with mechanisms involving MAPK-ERK pathway suppression.

bioRxiv · Jul 25, 2020 · PreprintCancer Biology